Will patients regain weight after GLP-1 receptor agonists are stopped?

This article was first published on April 10, 2024. It was last reviewed, updated, or edited on April 11, 2024. Glucagon-like peptide-1 (GLP-1) receptor agonists like semaglutide (Wegovy®) and tirzepatide (Zepbound®) are highly effective treatments for obesity and overweight in patients with or without diabetes. Even though these medications don’t have a specific FDA indication…